Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
Total Valuation
ALX Oncology Holdings has a market cap or net worth of $26.76M. The enterprise value is -$35.31M.
Market Cap$26.76M
Enterprise Value-$35.31M
Share Statistics
ALX Oncology Holdings has 53.38M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding53.38M
Owned by Insiders3.52%
Owned by Instutions38.81%
Financial Efficiency
ALX Oncology Holdings’s return on equity (ROE) is -1.19 and return on invested capital (ROIC) is -109.84%.
Return on Equity (ROE)-118.69%
Return on Assets (ROA)-91.25%
Return on Invested Capital (ROIC)-109.84%
Return on Capital Employed (ROCE)-110.20%
Revenue Per Employee$0
Profits Per Employee-$1,685,625
Employee Count80
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of ALX Oncology Holdings is -0.65. ALX Oncology Holdings’s PEG ratio is 0.02.
PE Ratio-0.65
PS Ratio0.00
PB Ratio0.77
Price to Fair Value0.77
Price to FCF-0.71
Price to Operating Cash Flow-0.71
PEG Ratio0.02
Income Statement
In the last 12 months, ALX Oncology Holdings had revenue of $0.00 and earned -$134.85M in profits. Earnings per share was -$2.60.
Revenue$0.00
Gross Profit-$434.00K
Operating Income-$142.47M
Pretax Income-$134.85M
Net Income-$134.85M
EBITDA-132.25M
Earnings Per Share (EPS)-2.60
Cash Flow
In the last 12 months, operating cash flow was -$121.91M and capital expenditures -$447.00K, giving a free cash flow of -$122.36M billion.
Operating Cash Flow-$121.91M
Free Cash Flow-$122.36M
Free Cash Flow per Share-$2.29
Dividends & Yields
ALX Oncology Holdings pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-140.43%
Earnings Yield-154.77%
Stock Price Statistics
Beta2.20
52-Week Price Change-96.64%
50-Day Moving Average0.87
200-Day Moving Average2.10
Relative Strength Index (RSI)35.85
Average Volume (3m)1.12M
Important Dates
ALX Oncology Holdings upcoming earnings date is May 8, 2025, After Close.
Last Earnings DateMar 6, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
ALX Oncology Holdings as a current ratio of 7.26, with Debt / Equity ratio of <0.01
Current Ratio7.26
Quick Ratio7.26
Debt to Market Cap<0.01
Net Debt to EBITDA0.13
Interest Coverage Ratio-82.40
Taxes
In the past 12 months, ALX Oncology Holdings has paid $170.72K in taxes.
Income Tax$170.72K
Effective Tax Rate0.00%
Enterprise Valuation
ALX Oncology Holdings EV to EBITDA ratio is -0.53, with an EV/FCF ratio of -0.57.
EV to Sales0.00
EV to EBITDA-0.53
EV to Free Cash Flow-0.57
EV to Operating Cash Flow-0.57
Balance Sheet
ALX Oncology Holdings has $127.76M in cash and marketable securities with $9.90M in debt, giving a net cash position of -$117.85M billion.
Cash & Marketable Securities$127.76M
Total Debt$9.90M
Net Cash-$117.85M
Net Cash Per Share-$2.21
Tangible Book Value Per Share$2.18
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for ALX Oncology Holdings is $4.63, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$4.63
Price Target Upside757.41%
Analyst ConsensusModerate Buy
Analyst Count6
Revenue Growth Forecast
EPS Growth Forecast30.37%